-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

664 Thrombocytopenia and Low CD4/CD8 Ratio at Apheresis Along with Prior Bendamustine Use Increase Risk of CAR-T Cell Manufacturing Failure

Program: Oral and Poster Abstracts
Type: Oral
Session: 711. Cell Collection and Processing I
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Biological therapies, Lymphomas, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, real-world evidence, Therapies, Lymphoid Malignancies
Sunday, December 11, 2022: 5:15 PM

Tomoyasu Jo, MD, PhD1,2*, Yasuyuki Arai, MD, PhD, FACP1,2, Satoshi Yoshihara, MD, PhD3,4*, Minoru Kojima5*, Junko Ikemoto4*, Tomoe Uemura6*, Keita Iwaki7*, Noboru Yonetani, MD8*, Shin-ichiro Fujiwara, MD, PhD9*, Masaki Ri10*, Kaoru Kahata, MD, PhD11*, Tokiko Nagamura-Inoue, MD, PhD12, Minami Yamada-Fujiwara, MD, PhD7,13* and Ryuji Tanosaki, MD, PhD14

1Department of Hematology and Oncology, Kyoto University Hospital, Kyoto, Japan
2Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan
3Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan
4Transfusion Medicine and Cell Therapy, Hyogo Medical University Hospital, Nishinomiya, Japan
5Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
6Center for Transfusion Medicine and Cell Therapy, Keio University Hospital, Tokyo, Japan
7Division of Blood Transfusion and Cell Processing, Tohoku University Hospital, Sendai, Japan
8Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
9Division of Cell Transplantation and Transfusion, Jichi Medical University, Shimotsuke, Japan
10Department of Hematology and Oncology, Nagoya City Univ. Grad. Sch. of Med. Sci., Nagoya, Japan
11Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan
12Department of Cell Processing and Transfusion, and IMSUT CORD, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
13Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan
14Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine, Tokyo, Japan


Chimeric antigen receptor T (CAR-T) cell therapy targeting CD19 has shown good outcomes in patients with relapsed or refractory (r/r) B-cell malignancies, and the number of patients awaiting this therapy is increasing dramatically. Successful CAR-T cell therapy can be achieved only after a number of steps are optimized. Of these, it is essential to ensure that CAR-T cells are manufactured without failure. Although manufacturing failure rates range from 1 to 13%, its causes and risk factors remain unclear. Therefore, we sought to determine risk factors for CAR-T cell manufacturing failure in a real-world setting.


This retrospective study, conducted by the Japan Society of Transfusion Medicine and Cell Therapy, enrolled patients who underwent CAR-T cell production for tisagenlecleucel (tisa-cel) using T cells harvested at 23 Japanese institutions from October 2019 to March 2022. Clinical factors, including patient characteristics, laboratory tests at apheresis, and apheresis procedures, were compared between successful and unsuccessful case groups. Categorical and continuous variables were compared between groups using Fisher’s exact test and two-tailed unpaired Student’s t-test, respectively. In comparison between groups, CD4/CD8 ratio was log-transformed to normalize skewed distribution. We evaluated the effect of each factor on the manufacturing outcome using a logistic regression model. p values <0.05 were considered statistically significant.


We analyzed 519 cases, including 438 diffuse large B-cell lymphoma (DLBCL) and 81 B-cell acute lymphoblastic leukemia (B-ALL) cases. Whereas no manufacturing failure was observed among B-ALL cases, there were 30 manufacturing failures (6.8%) among DLBCL cases. Then, we compared clinical factors between DLBCL cases that failed (n = 30) and that succeeded (n = 378), excluding those employed in clinical trials for out-of-spec products. The number of chemotherapy cycles performed prior to apheresis (median 13 vs. 10; p = 0.01) and the proportion of patients with previously treated with 3 or more cycles of bendamustine (43.3 vs. 10.9%; p < 0.01) were significantly higher in the failed group than the successful group. Regarding cell counts in peripheral blood at apheresis, platelet count (1.20 vs. 1.70 × 105/μL; p = 0.01) and CD4/CD8 ratio (0.30 vs. 0.56; p < 0.01) were significantly lower in the failed group than the successful group (Figure 1). For T-cell collection, Spectra Optia® was used in 403 cases (98.8%), and there were no significant differences in the failure rate in terms of the device type or collection program. There were no significant differences in the total number of CD3+ cells (3.1 vs. 2.9 ×109; p = 0.51) or proportion of CD3+ cells to total nucleated cells (55.6 vs. 46.4%; p = 0.14) shipped for tisa-cel production between the failed and successful groups. Multivariate logistic analysis revealed that history of 3 or more cycles of bendamustine therapy prior to apheresis (odds ratio [OR], 3.19; 95% confidence interval [CI], 1.04-9.82; p = 0.04), low platelet counts (OR, 0.52 per 105/μL; 95% CI, 0.28-0.96; p = 0.04), and low CD4/CD8 ratio (less than one third) (OR, 3.06; 95% CI 1.23-7.59; p = 0.02) in peripheral blood at apheresis were risk factors for CAR-T manufacturing failure.


This study showed that manufacturing failure remains an obstacle to CAR-T cell therapy. Repeated use of bendamustine prior to apheresis, low platelet counts, and low CD4/CD8 ratio in peripheral blood at apheresis were associated with increased risk of manufacturing failure. Avoiding these risk factors before apheresis and risk-adopted therapeutic strategy after apheresis may help to optimize CAR-T cell therapy for patients with r/r B-cell malignancies.

Disclosures: Jo: Nippon Shinyaku Co., Ltd.: Research Funding. Ri: Janssen Pharmaceutical: Honoraria; Bristol-Myers Squibb: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Daiichi Sankyo: Research Funding.

*signifies non-member of ASH